About Vitas Pharma
Vitas Pharma is a company based in Hyderabad (India) founded in 2011 by Rajinder Kumar and Radha Rangarajan. It operates as a B2B. Vitas Pharma has raised $484.45 thousand across 1 funding round from investors including Broadridge, GrayCell Ventures and Deep Kalra. Vitas Pharma operates in a competitive market with competitors including Spero Therapeutics, Nabriva, Melinta Therapeutics, Iterum Therapeutics and Adaptive Phage Therapeutics, among others.
- Headquarter Hyderabad, India
- Founders Rajinder Kumar, Radha Rangarajan
- Stage Minicorn
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
- Legal Name Vitas Pharma Research Private Limited
- Date of Incorporation 07 Jun, 2010
- Jurisdiction Hyderabad, Telangana, India
-
Annual Revenue
$147.06 K (USD)0as on Mar 31, 2020
-
Net Profit
-$471.37 K (USD)-18589.79as on Mar 31, 2020
-
EBITDA
-$8.16 K (USD)-314.62as on Mar 31, 2020
-
Total Equity Funding
$484.45 K (USD)
in 1 rounds
-
Latest Funding Round
$484.45 K (USD), Seed
Jan 17, 2015
-
Investors
Broadridge
& 43 more
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of Vitas Pharma
Vitas Pharma has successfully raised a total of $484.45K through 1 strategic funding round. The most recent funding activity was a Seed round of $484.45 thousand completed in January 2015. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Vitas Pharma
Vitas Pharma has secured backing from 44 investors, including angel, venture fund, and institutional investors. Prominent investors backing the company include Broadridge, GrayCell Ventures and Deep Kalra.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Angel network focused on India, Singapore, and U.S based companies
|
Locked | Locked | Locked | |
|
Angel investor network investing in early-stage startups
|
Locked | Locked | Locked | |
|
Technology company focused on building bonds through software.
|
Locked | Locked | Locked |
Investor details for Vitas Pharma
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Vitas Pharma
Investment portfolio details for Vitas Pharma
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Vitas Pharma
Detailed financials for Vitas Pharma
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Vitas Pharma Comparisons
Peer comparison for Vitas Pharma
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Vitas Pharma
Vitas Pharma operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Spero Therapeutics, Nabriva, Melinta Therapeutics, Iterum Therapeutics and Adaptive Phage Therapeutics, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Therapeutics for drug-resistant bacterial infections are developed.
|
|
| Locked | Locked | Locked |
Pleuromutilin antibiotics are developed for MDR infections.
|
|
| Locked | Locked | Locked |
Developer of bacterial ribosome-targeting drugs for MDR infections
|
|
| Locked | Locked | Locked |
Developer of antibiotics for MDR infections
|
|
| Locked | Locked | Locked |
Therapies for multi-drug resistant infections are developed using bacteriophages.
|
|
| Locked | Locked | Locked |
Therapeutics for antimicrobial resistant infections are developed.
|
Detailed competitors of Vitas Pharma
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Vitas Pharma
Complete news archive for Vitas Pharma
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Vitas Pharma
Vitas Pharma was founded in 2011 and raised its 1st funding round 4 years after it was founded.
Vitas Pharma is headquartered in Hyderabad, India. It is registered at Hyderabad, Telangana, India.
Radha Rangarajan is the current CEO of Vitas Pharma. They have also founded this company.
Vitas Pharma is a funded company, having raised a total of $484.45K across 1 funding round to date.
Annual revenue of Vitas Pharma is $147.06K as on Mar 31, 2020.
Vitas Pharma operates with a B2B model, focusing on providing healthcare solutions, biopharmaceuticals, drug development, and infectious disease therapeutics. An Indian preclinical-stage biopharma developing small molecule therapeutics for MDR bacterial infections. It emphasizes efficiency, client-focused solutions, and growth, fostering partnerships and innovation in its operations.
Vitas Pharma's top competitors include Spero Therapeutics, Melinta Therapeutics and Vedanta Biosciences.
Vitas Pharma has 44 investors. Key investors include Broadridge, GrayCell Ventures, Deep Kalra, Alok Mittal, and Sujan Parikh.
The valuation of Vitas Pharma is $2.41M as of Jan 2015.